companion animal vaccines market is on a steady rise as veterinary healthcare becomes a growing priority among pet owners. These vaccines play a crucial role in preventing common diseases in dogs, cats, and other pets—such as rabies, distemper, and feline leukemia. Market expansion is being driven by increasing pet ownership, improved access to veterinary services, and ongoing innovation in vaccine technology (like recombinant and DNA-based vaccines).
According to Fortune Business Insights, the companion animal vaccines market was valued at USD 5.43 billion in 2024. The market is projected to grow from USD 5.67 billion in 2025 to USD 8.71 billion by 2032, exhibiting a CAGR of 6.3% during the forecast period. In 2024, North America dominated the companion animal vaccines market with a market share of 43.46%.
In June 2024, Merck Animal Health unveiled its NOBIVAC NXT Rabies vaccine portfolio in Canada—covering both feline and canine formulations. This launch marks a significant upgrade in rabies immunization, addressing both conventional and emerging strains.
As households increasingly treat pets as family members, routine pet care—which includes vaccination—has become mainstream. Surprisingly simple data underlines this shift: for instance, Canada recorded a rise in dog population from 7.6 million to 7.7 million within two years. Simultaneously, zoonotic threats—transmittable diseases shared by animals and humans—have emphasized the importance of preventive measures.
The market is being redefined by next‑gen vaccine types—such as recombinant and DNA-based versions. Examples include Boehringer Ingelheim's 2024 launch of EURICAN L4 for canine leptospirosis, and Merck’s Nobivac oral Bordetella bronchiseptica plus parainfluenza vaccine. These innovations offer stronger immunity with fewer side effects.